首页> 外文学位 >Development and characterization of thermogels as voriconazole delivery vehicles in the treatment of fungal endophthalmitis.
【24h】

Development and characterization of thermogels as voriconazole delivery vehicles in the treatment of fungal endophthalmitis.

机译:热凝胶作为伏立康唑递送载体在真菌性眼内炎治疗中的开发和表征。

获取原文
获取原文并翻译 | 示例

摘要

Endophthalmitis, inflammation of internal ocular tissues, is often linked to poor surgical technique, contaminated intraocular lenses or penetrating ocular injuries. It is characterized by a decrease in visual acuity, severe pain and, if not treated, may lead to loss of vision. The risks associated with ocular tissue damage present a challenge in selecting a suitable drug delivery vehicle that can deliver the optimal therapeutic dose while minimizing further loss of tissue-function efficiency.;Voriconazole, a tri-azole drug administered currently via oral and intravenous infusion, has been shown to be a good alternative for treatment of fungal infections due to its broad spectrum of activity against a variety of fungi such as Candida spp., Aspergillus spp., Cryptococcus neoformans, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Fusarium spp. and Pennicillium marneffei. Most commonly used for antifungal treatment is Amphotericin B, which is often associated with organ toxicity at therapeutic levels e.g. irreversible kidney toxicity, increased liver enzymes, hepatotoxicity, cardiac arrest, skin reaction and electrolyte imbalance. AmBisome, a liposomal formulation of Amphotericin B mitigates some of these side effects while intrinsically possessing comparable anti-fungal efficacy. The drawbacks of use, however, are its expense and liposome-associated instability.;Voriconazole, at the doses used in the current modes of treatment, is associated with several side effects including transient visual disturbances, sepsis, diarrhea, peripheral edema, respiratory disorder and elevated hepatic enzyme levels. By reducing the dose administered, the risks and side effects associated with Voriconazole can be reduced.;Pluronic F127 and Tetronic 1107 are block copolymers of polyethylene oxide and polypropylene oxide and structurally have terminating primary hydroxyl groups. These chemical entities are also biodegradable and exhibit low toxicity. The amphiphilic nature of these polymers is attributed to the lipophilic PPO blocks covalently linked to the more hydrophilic PEO subunits. At concentrations between 15%--30%, solutions of F127 and Tetronic 1107 exhibit thermogelation i.e. as the temperature is increased, these micellar aqueous solutions gradually transition into gel-like matrices.;It was proposed that thermogeling systems can be used to deliver efficacious concentrations of Voriconazole to the ocular region by targeting drug administration to the site of action. The specific aims and milestones described in this manuscript support a feasible platform for delivery of Voriconazole to the vitreous humor at therapeutic levels capable of treating post-surgical invasive endophthalmitis, while also reducing the side effects associated with current modes of treatment. The proposed delivery vehicle will also minimize systemic tissue exposure associated with the current oral and/or intravenous modes of Voriconazole administration.
机译:眼内炎是眼内组织的炎症,通常与手术技术不佳,眼内晶状体污染或眼部穿透性损伤有关。其特点是视力下降,剧烈疼痛,如果不及时治疗,可能导致视力下降。与眼组织损伤相关的风险为选择合适的药物输送媒介带来了挑战,该媒介可以提供最佳治疗剂量,同时最大程度地降低组织功能效率的进一步下降。;伏立康唑,一种目前通过口服和静脉内输注给药的三唑类药物,由于其对多种真菌(例如念珠菌,曲霉,新型隐球菌,皮肤芽孢杆菌,皮肤炎球菌,球孢子菌性炎,荚膜组织胞浆,镰刀菌)的广泛活性,已被证明是治疗真菌感染的良好选择。和马尔尼菲青霉菌。最常用于抗真菌治疗的是两性霉素B,其通常在治疗水平例如器官毒性中与器官毒性有关。不可逆转的肾脏毒性,肝酶增加,肝毒性,心脏骤停,皮肤反应和电解质失衡。 AmBisome,一种两性霉素B的脂质体制剂,可减轻其中一些副作用,同时本质上具有可比的抗真菌功效。然而,使用的缺点是它的费用和与脂质体相关的不稳定性。;伏立康唑,以当前治疗方式所用的剂量,与多种副作用有关,包括短暂的视觉障碍,败血症,腹泻,外周水肿,呼吸系统疾病和肝酶水平升高。通过减少给药剂量,可以降低与伏立康唑有关的风险和副作用。Pluronic F127和Tetronic 1107是聚环氧乙烷和聚环氧丙烷的嵌段共聚物,在结构上具有末端伯羟基。这些化学实体也是可生物降解的,并且毒性低。这些聚合物的两亲性质归因于与更亲水的PEO亚基共价连接的亲脂PPO嵌段。当浓度在15%-30%之间时,F127和Tetronic 1107溶液表现出热凝胶化作用,即随着温度的升高,这些胶束水溶液逐渐转变成凝胶状基质。有人建议使用热凝胶化体系来提供有效的凝胶作用。通过将药物给药定向到作用部位来使伏立康唑浓度达到眼部区域。本手稿中描述的特定目标和里程碑为将伏立康唑以能够治疗手术后浸润性眼内炎的治疗水平递送至玻璃体液提供了可行的平台,同时还减少了与当前治疗方式相关的副作用。所提出的递送载体还将使与伏立康唑施用的当前口服和/或静脉内模式相关的全身组织暴露最小化。

著录项

  • 作者

    Muya, Leroy.;

  • 作者单位

    Mercer University.;

  • 授予单位 Mercer University.;
  • 学科 Health Sciences Pharmacology.;Health Sciences Pharmacy.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 140 p.
  • 总页数 140
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号